Anti-Progesterone Receptor (phospho S190) antibody [EP1516Y] (ab75857)

Overview

  • Product nameAnti-Progesterone Receptor (phospho S190) antibody [EP1516Y]
    See all Progesterone Receptor primary antibodies
  • Description
    Rabbit monoclonal [EP1516Y] to Progesterone Receptor (phospho S190)
  • Specificityab75857 detects Progesterone Receptor phophorylated at serine 190.
  • Tested applicationsSuitable for: WB, IP, ICC, IHC-Pmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Human
  • Immunogen

    A phospho specific peptide corresponding to residues surrounding serine 190 of human Progesterone Receptor

  • Positive control
    • T47D cell lysates, untreated or treated with progesterone; human breast carcinoma tissue.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

     

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

Properties

Applications

Our Abpromise guarantee covers the use of ab75857 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/5000 - 1/10000. Detects a band of approximately 99 kDa (predicted molecular weight: 99 kDa).
IP 1/50.
ICC 1/100 - 1/250.
IHC-P 1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
  • Application notesIs unsuitable for Flow Cyt.
  • Target

    • FunctionThe steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.
      Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.
      Isoform 4: Increases mitochondrial membrane potential and cellular respiration upon stimulation by progesterone.
    • Sequence similaritiesBelongs to the nuclear hormone receptor family. NR3 subfamily.
      Contains 1 nuclear receptor DNA-binding domain.
    • DomainComposed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain.
    • Post-translational
      modifications
      Phosphorylated on multiple serine sites. Several of these sites are hormone-dependent. Phosphorylation on Ser-294 occurs preferentially on isoform B, is highly hormone-dependent and modulates ubiquitination and sumoylation on Lys-388. Phosphorylation on Ser-102 and Ser-345 also requires induction by hormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 and Ser-400 is increased in response to progesterone and can be phosphorylated in vitro by the CDK2-A1 complex. Increased levels of phosphorylation on Ser-400 also in the presence of EGF, heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2 is ligand-independent, and increases nuclear translocation and transcriptional activity. Phosphorylation at Ser-162 and Ser-294, but not at Ser-190, is impaired during the G(2)/M phase of the cell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is required for interaction with SP1.
      Sumoylation is hormone-dependent and represses transcriptional activity. Sumoylation on all three sites is enhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388, the main site of sumoylation, is repressed by ubiquitination on the same site, and modulated by phosphorylation at Ser-294.
      Ubiquitination is hormone-dependent and represses sumoylation on the same site. Promoted by MAPK-mediated phosphorylation on Ser-294.
      Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
    • Cellular localizationNucleus. Cytoplasm. Nucleoplasmic shuttling is both homone- and cell cycle-dependent. On hormone stimulation, retained in the cytoplasm in the G(1) and G(2)/M phases; Mitochondrion outer membrane and Nucleus. Cytoplasm. Mainly nuclear.
    • Information by UniProt
    • Database links
    • Alternative names
      • NR3C3 antibody
      • Nuclear receptor subfamily 3 group C member 3 antibody
      • PGR antibody
      • PR antibody
      • PRA antibody
      • PRB antibody
      • PRGR_HUMAN antibody
      • Progesterone receptor antibody
      • Progestin receptor form A antibody
      • Progestin receptor form B antibody
      see all

    Anti-Progesterone Receptor (phospho S190) antibody [EP1516Y] images

    • ab75857 at 1/100 dilution staining Progesterone Receptor in human breast carcinoma by Immunohistochemistry, Paraffin-embedded tissue.
    • All lanes : Anti-Progesterone Receptor (phospho S190) antibody [EP1516Y] (ab75857) at 1/10000 dilution

      Lane 1 : T47D cell lysates, untreated
      Lane 2 : T47D cell lysates, treated with progesterone

      Lysates/proteins at 10 µg per lane.

      Secondary
      goat anti-rabbit HRP at 1/2000 dilution

      Predicted band size : 99 kDa
      Observed band size : 99,118 kDa (why is the actual band size different from the predicted?)

    References for Anti-Progesterone Receptor (phospho S190) antibody [EP1516Y] (ab75857)

    This product has been referenced in:
    • Harigopal M  et al. Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 176:1639-47 (2010). Read more (PubMed: 20150438) »

    See 1 Publication for this product

    Product Wall

    There are currently no Abreviews or Questions for ab75857.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"